Adcentrx Therapeutics Announces FDA Clearance of Investigational New Drug Application for ADRX-0405, a Potential First-in-Class ADC Targeting STEAP1 for the Treatment of Advanced Solid Tumors

Second asset utilizing Adcentrx’s ADC platform to receive IND clearance Dosing of first patient in a Phase 1a/b clinical trial anticipated by 4Q 2024 SAN DIEGO, Oct. 21, 2024 /PRNewswire/ — Adcentrx Therapeutics (“Adcentrx”), a clinical-stage biotechnology company advancing innovative…